Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10880354 
Lizcano JM, Morrice N, Cohen P (2000) Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J 349, 547-57 10880354
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S112-p - BAD (mouse)
Orthologous residues
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKACA (cow)
KINASE p90RSK (mouse)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p90RSK (human) pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
forskolin no change compared to control
IBMX, forskolin no change compared to control
EGF increase
PD98059 EGF inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
wortmannin EGF no effect upon treatment-induced increase
rapamycin EGF no effect upon treatment-induced increase
Ro31-8220 EGF inhibit treatment-induced increase
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase
U0126 phorbol ester inhibit treatment-induced increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
wortmannin phorbol ester no effect upon treatment-induced increase
rapamycin phorbol ester no effect upon treatment-induced increase
IGF-1 no change compared to control

S136-p - BAD (mouse)
Orthologous residues
BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
KINASE PKACA (cow)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
forskolin no change compared to control
IBMX, forskolin no change compared to control
EGF no change compared to control
phorbol ester no change compared to control
IGF-1 no change compared to control

S155-p - BAD (mouse)
Orthologous residues
BAD (human): S118‑p, BAD (mouse): S155‑p, BAD (rat): S156‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKACA (cow)
KINASE MSK1 (human)
KINASE p90RSK (mouse)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKACA (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
forskolin increase
IBMX, forskolin increase
H-89 forskolin, IBMX inhibit treatment-induced increase
Ro31-8220 forskolin, IBMX no effect upon treatment-induced increase
PD98059 forskolin, IBMX no effect upon treatment-induced increase
rapamycin forskolin, IBMX no effect upon treatment-induced increase
wortmannin forskolin, IBMX no effect upon treatment-induced increase
EGF no change compared to control
phorbol ester no change compared to control
IGF-1 no change compared to control
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 gamma (mouse) Induces in vitro, pull-down assay
Bcl-xL (mouse) Disrupts in vitro, pull-down assay


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.